Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA08WU
|
|||
| Drug Name |
EDP-938
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Phase 2 | [1] | |
| Company |
Enanta Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Respiratory syncytial virus protein N (RSV N) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04816721) A Study to Evaluate EDP 938 Regimens in Infants With RSV (RSVPEDs). U.S. National Institutes of Health. | |||
| REF 2 | EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog. 2021 Mar 15;17(3):e1009428. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.